• FDA cleared Takeda’s MIMRYLO (rusfertide) for erythrocytosis in adults with polycythemia vera.
• Protagonist will receive USD 275 million in milestone payments tied to the approval.
• Deal includes 14%-29% tiered royalties on worldwide net sales, with up to USD 875 million in additional potential milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608282030ACCESSWRNAPR_____1214342) on August 29, 2026, and is solely responsible for the information contained therein.